FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
64%chance▲ 10
Install
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)
The odds
81%chance▼ 1
How the odds have moved
Yes: 82% on Nov 3, 81% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 81% | ▼ 1 | 77¢ | 85¢ | $1.18 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, United Therapeutics, Ralinepag
Search ›- United Therapeutics secures FDA clearance for PAH Phase I trialUnited Therapeutics has received clearance from the US Food and Drug Administration (FDA) under an investigational new drug application (IND) to initiate a Phase I trial assessing Treprostinil-Iloprost SMI as a potential treatment for…
- United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial HypertensionIf successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH) This investigational therapy combines two potent prostacyclin analogues…
- United Therapeutics cleared for phase 1 trial of treprostinil-iloprost SMIFDA clears United Therapeutics' phase 1 trial for treprostinil-iloprost SMI in pulmonary arterial hypertension. - The US FDA has granted clearance for United Therapeutics (UTHR) to conduct a phase 1 open-label, single ascending dose study…
- Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,592,080.00 in StockPosted by Sarita Garza on Oct 27th, 2026 Check Out Our Latest Stock Analysis on United Therapeutics The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer…
- United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company StockShares of UTHR stock opened at $592.84 on Tuesday. The stock has a market cap of $25.43 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 4.26 and a beta of 0.49. The stock has a 50-day moving average of $521.24 and a 200-day…
- Billionaire Martine Rothblatt Sells $5.5 Million in United Therapeutics SharesMartine Rothblatt, chairperson and chief executive of United Therapeutics, sold 9,500 shares of the biotechnology company on October 22 for about $5.5 million, according to a regulatory filing reported by Billionaires.Africa. She first…
- FDA clears soft mist inhaler trial for lung diseaseThe trial is called SUMMIT, and before getting into it, the condition deserves a proper introduction because most people haven’t heard of it. COPD is a group of serious, progressive lung diseases with no cure, and United Therapeutics…
- RFK Jr. eases restrictions on some peptides not approved by FDACBS News Philadelphia is a local news organization that is part of CBS News and Stations. Also referred to as KYW-TV and channel 3, CBS News Philadelphia offers local breaking news, weather coverage and investigative reporting. RFK Jr…
- RFK Jr. eases restrictions on six peptides not approved by FDACBS News Texas is a local news organization that is part of CBS News and Stations. Also referred to as KTVT and channel 11, CBS News Texas offers local breaking news, weather coverage and investigative reporting. RFK Jr. eases restrictions…
- FDA zooms in on rare disease reviewsDelivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy. 10/27/2026 12:00 PM EDT A NOT-SO ‘RARE’ FOCUS — The FDA’s recently announced effort to reimagine the review process for…
- FDA Approved an Antibiotic Based on Bogus Data -- but the Courts Don't CareUpdated on: February 18, 2011 / 6:34 PM EST / MoneyWatch The Ketek antibiotic scandal at Sanofi-Aventis (SNY) is receding into ancient history (if you agree that 2007 is "ancient"), so it's not until you read this new class action ruling…
- HIV prevention drug lenacapavir approved by FDA as twice-yearly injectionUpdated on: June 18, 2025 / 8:07 PM EDT / CBS News The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved…
Related markets
All fda & drugs ›When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
97%before April 2027
- before April 202797%▼ 1
- before 202794%▲ 2
- before December93%▲ 10
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
13%chance▼ 5
When will Beam Therapeutics submit a BLA for Risto-cel?
70%before April 2027
- before April 202770%
- before 202746%▼ 1
- before December28%▲ 9
Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 4, 2027even chance by
- Before Jan 1, 20271%
- Before Jul 1, 202721%▼ 2
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
When will the FDA reclassify BPC-157 to Category 1?
11%Before 2027
- Before 202711%▲ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Search. Prices read from the venues 11 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Search, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Search index; prices of stocks, rates and coins from 4Search Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions